Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest BD Diagnostics Stories

2011-04-26 15:01:00

FRANKLIN LAKES, N.J., April 26, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.922 billion for the second fiscal quarter ended March 31, 2011, representing an increase of 6.8 percent from the prior-year period. On a foreign currency-neutral basis, revenue increased 4.6 percent, despite an unfavorable comparison to the prior year of about 2.3 percentage points due to strong sales...

2011-02-07 15:04:00

FRANKLIN LAKES, N.J., Feb. 7, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.842 billion for the first fiscal quarter ended December 31, 2010, representing a decrease of 1.4 percent from the prior-year period. On a foreign currency-neutral basis, revenue decreased 1.5 percent. The revenue decline reflects an unfavorable comparison to the prior year of about 4 percentage points due...

2011-02-04 06:15:00

RALEIGH, N.C., Feb. 4, 2011 /PRNewswire-USNewswire/ -- The National Cancer Coalition (NCC) and BD (Becton, Dickinson and Company), a leading global medical technology company, are pleased to announce the implementation of a cervical cancer early detection program to benefit 75,000 underserved women in Peru. With a goal to reduce the high cervical cancer mortality levels in the mountainous region surrounding Cusco, this extensive three-year program is set to conduct liquid-based cytology...

2011-01-03 14:00:00

DURHAM, N.C., Jan. 3, 2011 /PRNewswire/ -- Clinicians may soon have a new tool in the diagnosis and treatment of Herpes Simplex Viruses (HSV) - one of the most common sexually transmitted infections in the world. BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today that it filed for U.S. Food and Drug Administration (FDA) 510(k) clearance for the first fully automated molecular tests to diagnose and differentiate HSV types 1 and 2. "When caring...

2010-11-03 16:24:00

FRANKLIN LAKES, N.J., Nov. 3, 2010 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.873 billion for the fourth fiscal quarter ended September 30, 2010, representing an increase of 1.0 percent from the prior-year period, or 2.9 percent on a foreign currency-neutral basis. For the full fiscal year ended September 30, 2010, BD reported revenues of $7.372 billion, representing an...

2010-08-03 08:50:00

BALTIMORE, Aug. 3 /PRNewswire-FirstCall/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today that it has received "Moderate Complexity" status from the U.S. Food and Drug Administration, under the Clinical Laboratory Improvement Amendments (CLIA), for the BD MAX(TM) GBS Assay for Group B Streptococcus (GBS) on the BD MAX(TM) System. With the "Moderate Complexity" categorization, the BD MAX GBS Assay will increase access to cost effective...

2010-07-29 07:00:00

FRANKLIN LAKES, N.J., July 29 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the promotion of Vincent A. Forlenza, President, who assumes the title of Chief Operating Officer in addition to his current title. Mr. Forlenza will continue to report to Edward J. Ludwig, Chairman and Chief Executive Officer. "This new title reflects the additional duties that Vince has taken on during the last two years and...

2010-07-29 04:15:00

FRANKLIN LAKES, N.J., July 29 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.878 billion for the third fiscal quarter ended June 30, 2010, representing an increase of 3.2 percent from the prior-year period, or 3.9 percent on a foreign currency-neutral basis. "We are pleased with our results this quarter, with each of our three segments contributing to our growth. We delivered...

2010-06-02 10:08:00

BALTIMORE, June 2 /PRNewswire-FirstCall/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market the BD MAX(TM) GBS Assay for Group B Streptococcus (GBS) on the BD MAX(TM) System. The BD MAX System is a next-generation automated workstation for molecular testing designed to streamline workflow and offer full walkaway automation to accommodate varying workloads...

2010-04-29 05:00:00

FRANKLIN LAKES, N.J., April 29 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) today reported quarterly revenues of $1.845 billion for the second fiscal quarter ended March 31, 2010, representing an increase of 7.0 percent from the prior-year period, or 6.6 percent on a foreign currency-neutral basis. "We are pleased with our second quarter results, which are in line with the Company's expectations," said Edward J. Ludwig, Chairman and Chief Executive Officer....